Effectiveness of PHR-160 spray in recovery of hospitalized patients with Covid-19 in Isfahan province in 1399

Evaluation of the effectiveness of PHR-160 spray in recovery of hospitalized patients with Covid-19 in Isfahan province in 1399

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200411047029N1

Enrollment

198

Registered

2021-04-24

Start date

2021-04-21

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: PHR 160 spray, which contains 160 micrograms of active ingredient in each puff, 2 puffs every 2 hours during the awakening period using Damiar with national standar

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 18 years Definite diagnosis of SARS-CoV-2 virus based on PCR Diagnosis of pneumonia consistent with lung involvement with COVID-19 on CT scan Need to be admitted to the ICU at the beginning of hospitalization

Exclusion criteria

Exclusion criteria: Having comorbidities (chronic kidney failure, cirrhosis, severe heart failure (less than 25% EF), active or untreated cancer) Pregnancy and breastfeeding Patients with hepatic enzymes including aspartate transaminase (AST) and alanine transaminase (ALT) at 5 times more than normal amount

Design outcomes

Primary

Measure	Time frame
Duration and severity of symptoms (cough and shortness of breath). Timepoint: Daily. Method of measurement: Case file-Query from patients.;Duration of hospitalization. Timepoint: Daily. Method of measurement: Case file.;Blood oxygen levels. Timepoint: Daily. Method of measurement: Pulse Oximeters.;Requirement for ICU admission. Timepoint: Daily. Method of measurement: Doctor diagnosis.;Duration of hospitalization in the ICU. Timepoint: Daily. Method of measurement: Case file.;Death rate. Timepoint: Daily. Method of measurement: Case file.	—

Measure

Time frame

Duration and severity of symptoms (cough and shortness of breath). Timepoint: Daily. Method of measurement: Case file-Query from patients.;Duration of hospitalization. Timepoint: Daily. Method of measurement: Case file.;Blood oxygen levels. Timepoint: Daily. Method of measurement: Pulse Oximeters.;Requirement for ICU admission. Timepoint: Daily. Method of measurement: Doctor diagnosis.;Duration of hospitalization in the ICU. Timepoint: Daily. Method of measurement: Case file.;Death rate. Timepoint: Daily. Method of measurement: Case file.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Sami

Esfahan University of Medical Sciences

r.sami@med.mui.ac.ir+98 31 3222 2892

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026